OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results

Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits EGFR-TKI sensitising and EGFR T790M resistance mutations, has demonstrated efficacy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC), including central nervous system metastases. Adjuvant osimertinib was approved for treatment of patients with completely resected stage IB-IIIA EGFRm NSCLC based on results (data cut-off 17 Jan 2020) of the Phase III ADAURA trial (NCT02511106), which showed a statistically significant and clinically meaningful disease-free survival (DFS) benefit with adjuvant osimertinib vs placebo (DFS HR in stage IB-IIIA, 0.20; 99.12% CI, 0.14, 0.30; p<0.001). Fewer patients had disease recurrence with osimertinib (11%) vs placebo (46%) and there was a clinically meaningful improvement in central nervous system DFS (intracranial DFS) with osimertinib (HR, 0.18; 95% CI 0.10, 0.33; p<0.0001) vs placebo. We will report updated exploratory analyses of DFS and recurrence patterns after 2 years added follow up.